Ignite Creation Date:
2024-05-06 @ 8:27 AM
Last Modification Date:
2024-10-26 @ 12:00 PM
Study NCT ID:
NCT02735707
Status:
RECRUITING
Last Update Posted:
2024-07-12
First Post:
2015-12-11
Brief Title:
Randomized Embedded Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Sponsor:
UMC Utrecht
Organization:
UMC Utrecht
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Community-acquired Pneumonia Influenza COVID-19 |
Keywords:
| Name | View |
|---|---|
| Ivermectin | View |
| Pneumonia | View |
| Lung Diseases | View |
| Respiratory Tract Diseases | View |
| Respiratory Tract Infections | View |
| Anti-Bacterial Agents | View |
| Moxifloxacin | View |
| Levofloxacin | View |
| Antibiotics | View |
| Hydrocortisone | View |
| Anti-Infective Agents | View |
| Ceftriaxone | View |
| Piperacillin-tazobactam | View |
| Ceftaroline | View |
| Amoxicillin-clavulanate | View |
| Oseltamivir | View |
| COVID-19 | View |
| Influenza | View |
| Intensive care | View |
| Critical care | View |
| SARS-CoV-2 | View |
| Vitamin C | View |
| Therapeutic Anticoagulation | View |
| Statin | View |
| Invasive Mechanical Ventilation | View |
| Convalescent plasma | View |
| Eritoran | View |
| Apremilast | View |
| DMX-200 | View |
| Baloxavir | View |
| Tocilizumab | View |
| Baricitinib | View |
| Imatinib | View |